Study Analyzed SYMBICORT In Children With Persistent Asthma

Armen Hareyan's picture
Advertisement

A new 12-week study examined safety and efficacy measures of the maintenance combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dehydrate) Inhalation Aerosol in treating mild to moderate persistent asthma in children ages 6 to 15 years old who were previously treated with an inhaled corticosteroid (ICS). Of note, the study included efficacy assessments of nighttime symptoms, nighttime rescue medication use and rescue medication-free days in patients taking SYMBICORT compared to those taking formoterol dry powder inhaler (DPI) or budesonide pressurized metered-dose inhaler (pMDI).

Advertisement